NanoBio® Promotes David Peralta to Chief Executive Officer

<0> Schwartz MSLBenjamin Navon, 781-684-0770 </0>

today announced the promotion of David Peralta to chief executive officer. Mr. Peralta, who previously served as the company’s chief operating and financial officer, replaces James R. Baker, Jr. M.D., who recently joined Merck & Co. as the senior vice president, head global vaccine franchise. As the scientific founder and inventor of NanoBio’s patented NanoStat™ technology platform, Dr. Baker will continue to serve on NanoBio’s Board of Directors.

Mr. Peralta joined NanoBio in February 2006. During his tenure, Mr. Peralta has been directly responsible for the company’s business development, fundraising and finance-related activities, in addition to managing the company’s day-to-day operations. Previously, Mr. Peralta served as vice president and chief financial officer for Arbortext, Inc., a venture-backed enterprise software company, where he played a key role in accelerating the company’s growth, which ultimately led to Arbortext being acquired in 2005. Prior to joining Arbortext, Mr. Peralta was chief financial officer of Mechanical Dynamics, Inc. (NASDAQ:MDII), a publicly-held software company, where he directed all finance and investor relations activities during the company’s initial public offering in 1996 and up through the sale of the company in 2002.

“I am honored and excited to lead NanoBio,” said Mr. Peralta. “I believe that NanoBio can play a very important role in the future of medicine. We are on the forefront of harnessing nanotechnology to safely treat some of the most troublesome skin and lung infections. In addition, we are making great strides in terms of utilizing our NanoStat™ technology to enable intranasal and intramuscular vaccines for diseases that today have no vaccine available. I wish Jim all the best in his new role at Merck, and I look forward to continuing to work closely with him as a member of our board of directors.”

NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat® technology platform. The company’s lead product candidates are treatments for herpes labialis, onychomycosis, vaginitis, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.